For patients planning pregnancy, semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long half-life, while tirzepatide may persist for approximately 1 month
Data analysis A population-based pharmacovigilance study utilizing a case/non-case approach was employed to investigate the potential association between GLP-1RA and reports of suicidal tendencies and/or self-injury
GI side effects A recent systematic review of 39 randomized controlled trials of GLP-1RAs showed a class effect of increased risks of nausea, vomiting, diarrhea and constipation compared with placebo (15) in individuals without diabetes
Popular GLP-1 medications include: Semaglutide (Ozempic, Wegovy) Liraglutide (Victoza, Saxenda) Tirzepatide (Mounjaro, Zepbound) Dulaglutide (Trulicity) Exenatide (Byetta) These medications were first approved to treat type 2 diabetes but are now also used to help people with obesity lose weight
Individual response to GLP-1 medications varies